Brii Bio Strengthens Position with Acquisition of BRII-179 IP Rights and Completes Patient Enrollment for ENRICH Study#China#Beijing#Brii_Bio#BRII-179#HBV_Therapy
Brii Bio Strengthens Position with Acquisition of BRII-179 IP Rights and Completes Patient Enrollment for ENRICH Study
Brii Biosciences Limited enhances its future with the acquisition of BRII-179 intellectual property rights and successful enrollment in the ENRICH study, aiming at improved HBV therapies.
third-news.com
December 31, 2024 at 11:20 AM
Brii Bio Strengthens Position with Acquisition of BRII-179 IP Rights and Completes Patient Enrollment for ENRICH Study#China#Beijing#Brii_Bio#BRII-179#HBV_Therapy